Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bataille, R
Right arrow Articles by Pellat-Deceunynck, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bataille, R
Right arrow Articles by Pellat-Deceunynck, C
Haematologica, Vol 91, Issue 9, 1234-1240
Copyright © 2006 by Ferrata Storti Foundation

Journal Article

The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy

R Bataille, G Jego, N Robillard, S Barille-Nion, JL Harousseau, P Moreau, M Amiot, and C Pellat-Deceunynck

INSERM, U601, Nantes, France.

The aim of this review is to integrate non-exhaustive relevant data on the phenotype of human plasma cells (PC), including normal, reactive and malignant (multiple myeloma, MM) PC. This review focuses on (i) a universal marker of both normal and malignant plasma cells, CD138; (ii) markers related to malignancy i.e., CD19, CD27, CD28, and CD56; (iii) markers associated with signaling and severity of MM (CD45, CD221). Finally, this review presents data from normal PC up to human myeloma cell lines in order to: (i) define different entities of MM based on expression of CD19, CD20, CD27 and CD117; and (ii) identify new therapeutic targets.


This article has been cited by other articles:


Home page
 JCOHome page
G. Mateo, M. A. Montalban, M.-B. Vidriales, J. J. Lahuerta, M. V. Mateos, N. Gutierrez, L. Rosinol, L. Montejano, J. Blade, R. Martinez, et al.
Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy
J. Clin. Oncol., June 1, 2008; 26(16): 2737 - 2744.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. E. Craig and K. A. Foon
Flow cytometric immunophenotyping for hematologic neoplasms
Blood, April 15, 2008; 111(8): 3941 - 3967.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Romagnoli, G. Desplanques, S. Maiga, S. Legouill, M. Dreano, R. Bataille, and S. Barille-Nion
Canonical Nuclear Factor {kappa}B Pathway Inhibition Blocks Myeloma Cell Growth and Induces Apoptosis in Strong Synergy with TRAIL
Clin. Cancer Res., October 15, 2007; 13(20): 6010 - 6018.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.